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β-AdrenoceptorGTP binding proteins are classiﬁed into two families: heterotrimeric large G proteins which are composed of
three subunits, and one subunit of small G proteins. Roles of small G proteins in the intracellular trafﬁcking of
G protein-coupled receptors (GPCRs) were studied. Among various small G proteins tested, GTP-bound form
(G23V) of RalA inhibited the internalization of dopamine D2 receptor independently of the previously reported
downstream effectors of RalA, such as Ral-binding protein 1 and PLD. With high afﬁnity for GRK2, active RalA
inhibited the GPCR endocytosis by sequestering the GRK2 from receptors. When it was tested for several
GPCRs including an endogenous GPCR, lysophosphatidic acid receptor 1, agonist-induced conversion of GTP-
bound to GDP-bound RalA, which presumably releases the sequestered GRK2, was observed selectively with
the GPCRswhichhave tendency to undergo endocytosis. Conversion of RalA fromactive to inactive state occurred
by translocation of RGL, a guanine nucleotide exchange factor, from the plasma membrane to cytosol as a com-
plex with Gβγ. These results suggest that agonist-induced Gβγ-mediated conversion of RalA from the GTP-
bound form to the GDP-bound form could be amechanism to facilitate agonist-induced internalization of GPCRs.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Agonist binding induces conformational changes of G protein-
coupled receptors (GPCRs) and stimulates the dissociation of Gα from
Gβγ, leading to the control of different effectors and regulation of
receptor responsiveness. According to the current paradigmofGPCR reg-
ulation, dissociated Gβγmediates the recruitment of GPCR kinase2 or 3
(GRK2 or GRK3) which possesses PH domain to the receptors to phos-
phorylate them [1,2]. Phosphorylated receptors display increased afﬁnity
for β-arrestins, and β-arrestins are translocated from cytosol to the plas-
mamembrane where agonist-occupied receptors are located [3]. Within
minutes of agonist exposure, activated receptors undergo the process of
endocytosis. Several key cellular elements have been reported to be in-
volved in the process of receptor endocytosis, for example, AP2 and
epsins which are adaptors and sorting proteins, respectively [4].
GTP binding proteins are classiﬁed into two families: heterotrimeric
large G proteins which are composed of three subunits (α, β, and γ),
and one subunit of small G proteins. In contrast to the heterotrimeric
G protein family, which contains only several members havingcology, College of Pharmacy,
lic of Korea.relatively conserved functions,much larger numbers of small G proteins
with highly variable functions have been reported [5,6].
Ral belongs to small GTPases of the Ras super-family, and has multi-
ple regulatory roles such as gene transcription, cytoskeletal regulation,
cell differentiation and migration [5,7–9]. In addition, several lines of
evidence have implicated the roles of Ral in the endocytosis of receptor
proteins [10]. For example, Ral inhibits the clathrin-dependent endocy-
tosis of transferrin, activin, insulin, and EGF receptors via the recruit-
ment of Ral-binding protein 1 (RalBP1) [11–13].
Among several small G proteins tested in our preliminary study,
active RalA showed inhibitory activities on D2R endocytosis. In this
study, we wanted to understand the relationship between the activities
of RalA and endocytosis of D2R. We also questioned whether the
mechanism obtained from D2R could be extended to other GPCRs as a
principle to explain the endocytosis of other GPCRs.
2. Materials and methods
2.1. Materials
Dopamine (DA), isoproterenol (ISO), anti-FLAGM2 antibodies, anti-
FLAG-conjugated agarose beads, antibodies to actin and green ﬂuores-
cence protein (GFP), horseradish peroxidase (HRP)-labeled secondary
antibodies, and glutathione beads were purchased from Sigma/Aldrich
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purchased from Cayman Chemical (Ann Arbor, MI, USA). [3H]-Sulpride
(87 Ci/mmol) and [3H]-CGP-12,177 (41.7 Ci/mmol) were purchased
from PerkinElmer Life Sciences (Boston, MA, USA). Antibodies to
LPAR1 were purchased from Abcam (Cambridge, MA, USA). Antibodies
to HA epitope, RalA, phosphoserine, MDM2 and GRK2 were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to β-
arrestins were provided by Dr. Robert Lefkowitz (Duke University,
Durham, NC, USA).
2.2. DNA constructs
Wild-type (WT) human D2R and D3R in pCMV5, D2R, D3R and
MDM2 tagged at the N-terminus with the M2-FLAG epitope, and β-
arrestin2 constructs were previously described [14,15]. Flag-tagged
human β2AR and AT1R were prepared by polymerase chain reactions.
HA-tagged LPAR1 was provided by Dr. S. Na (Konkuk University,
Korea). GRK2-CT was previously described [16]. Yellow ﬂuorescence
protein (YFP)-Gβ1 [17], RalBP1 and POB1constructs [11], and Ral
constructs [18,19], were reported previously. Small hairpin RNA
(shRNA) of GRK2 [20], β-arrestin1/β-arrestin2 [21], and MDM2 [22]
was described previously. ΔN11-G23V-RalA and GFP-RGL were pre-
pared by site-directed mutagenesis or by polymerase chain reactions.
2.3. Endocytosis assay
Endocytosis of D2R and β2ARwasmeasured based on the hydrophil-
ic properties of [3H]-sulpiride and [3H]-CGP-12,177 [14,23]. HEK-293
cells expressing D2R or β2AR were seeded 1 day after transfection at a
density of 1.5 x 105 cells/well in 24-well plates. The following day, the
cells were rinsed once and pre-incubated for 15 min with 0.5 ml of
pre-warmed serum-free medium containing 10 mM HEPES, pH 7.4, at
37 °C. The cells were stimulated with 10 μM DA or ISO for 0–60 min as
indicated. The cells were then incubated with 250 μl of [3H]-sulpiride
(ﬁnal concentration 2.2 nM) or [3H]-CGP-12,177 (ﬁnal concentration
10 nM) at 4 °C for 150 min in the absence and presence of unlabeled
competitive inhibitor (10 μM haloperidol or propranolol). The cells
were washed three times with the same medium and 1% SDS was
added. The samples were mixed with 2 ml Lefkoﬂuor scintillation ﬂuid
and counted on a liquid scintillation analyzer. The endocytosis of D3R
was determined by ELISA method or ﬂow cytometry as described
previously [14].
2.4. Whole cell phosphorylation
HEK-293 cells were seeded one day after transfection at a density of
~1 x 106 cells/25-mm well. Cells were stimulated with 10 μM DA for
5 min. The [32P]-labeled phosphorylated receptors were assessed by
autoradiography. The detailed procedures are described elsewhere
[14]. For the normalization of the loading volumes, the amount of
receptor in each sample was determined by saturation binding with
3 nM [3H]-spiperone.
2.5. Immunoprecipitation
Cells were lysed in lysis buffer (150 mM NaCl, 50 mM Tris, pH 7.4,
1 mM EDTA, 1% Triton X-100, 10% glycerol) on a rotation wheel for
4 h at 4 °C. Supernatant was combined with 25 μl of a 50% slurry of
agarose beads coated with anti-FLAG antibodies for 2–3 h on a rotation
wheel. Beads were washed with washing buffer (50 mM Tris, pH 7.4,
137 mM NaCl, 10% glycerol, 1% NP-40) three times for 5 min each. The
resulting immunoprecipitateswere separated by SDS-PAGE, transferred
to nitrocellulose membrane. The membrane was blotted with antibod-
ies to corresponding target proteins.2.6. Measurement of GTP-bound RalA
Activation of Ral was measured by a glutathione-S-transferase
(GST)-pull down assay using an activation-speciﬁc probe, the Ral-
binding domain (397–518 amino acid residues) of RalBP (RBD) [24].
For this, RBD was bacterially expressed as a fusion protein with
glutathione-S-transferase (GST-RBD). Cell lysates obtained from the
HEK-293 cells transfected with corresponding GPCRs and GFP-RalA
cDNA were added to the column containing GST-RBD pre-coupled to
glutathione-agarose beads and incubated for 45 min with continuous
shaking at 4 °C. Beads were washed four times with GST-binding buffer
and then treated with Laemmli sample buffer. For the measurement of
endogenous RalA activities, eluents of GST pull-down were blotted
with antibodies against RalA.2.7. Immunocytochemistry
The HEK-293 cells were plated on cover slips, ﬁxed with 4% parafor-
maldehyde in PBS for 10 min at room temperature. Cells were perme-
abilized with 0.1% Triton X-100 in PBS at room temperature. Cells
were incubated with PBS containing 3% fetal bovine serum and 1% bo-
vine serum albumin for 1 h and then incubated with FLAG, GRK2, and
HA antibodies at 1:1000 dilutions for 1 h at room temperature. For the
detection of endogenous LPAR1, antibodies against LPAR1 were used
at 1:50 dilutions. After three washes, cells were incubated with Alexa
555- conjugated anti-mouse antibodies or Alexa 647-conjugated anti-
rabbit antibodies (Invitrogen, Carlsbad, CA, USA) at 1:500 dilutions.
After three washes with washing buffer, the cells were mounted in a
Vectashield (Vector Laboratories, Burlingame, CA, USA) and viewed by
a laser scanning confocal microscope (TCS SP5/ABOS/Tandem,
Germany).2.8. Data analyses
Thevalues are expressed asmean±SEM for thenumber of indepen-
dent experiments indicated in the ﬁgure legends. Student's t-test was
used to compare results. A p-value b0.05 was considered signiﬁcant.
Comparisons among experimental groups were performed using
ANOVA and Tukey's simultaneous test.3. Results
3.1. RalA regulates the internalization of dopamine D2 receptor and β2
adrenergic receptor in an activity-dependent manner
In order to study the roles of small G proteins on the intracellular
trafﬁcking of GPCRs, effects of small G proteins, such as Rab5, Rab23,
ARF1, ARF6, and RalA were tested for the internalization of dopamine
D2 receptor (D2R). These small G proteins are known to be involved
in various processes such as vesicle formation, scission, targeting,
and fusion formation [25,26]. Among these small G proteins, an ac-
tive RalA mutant (GTP hydrolysis-resistant form, G23V) but not an
inactive RalA mutant (GDP bound form, S28N) [8,9] inhibited the
endocytosis of D2R in HEK-293 cells (Fig. 1A) and SH-SY5Y dopami-
nergic neuroblatoma cell lines (Fig. 1B), which are physiologically
relevant cells for dopaminergic functions. WT-RalA also inhibited
the endocytosis of D2R but at lower extent.
Essentially the same results were observed with β2 adrenergic
receptor (β2AR). As shown in the left panel of Fig. 1C, agonist stimu-
lation of HEK-293 cells expressing β2AR-GFP (green ﬂuorescence
protein) resulted in the endocytosis of β2AR in the endocytic
vesicles, which was clearly inhibited in the cells expressing G23V-
RalA (3rd panel).
Fig. 1. RalA inhibits the endocytosis of dopamine D2 receptor and β2 adrenergic receptor in an activity-dependent manner. (A) Roles of small GTP binding proteins in the endocytosis of
D2R. HEK-293 cells expressingD2Rwere transfectedwithWT, active (G23V), and inactive (S28N) RalA;WT anddominant negative (N34) Rab5;WTand dominant negative (S23N) Rab23;
WT, dominant negative (T31N), and constitutively active (Q71L) ARF1; WT, inactive (T27N), and active (Q67L) ARF6. Expression levels of D2R were maintained between 1.1 and
1.4 pmol/mg protein. **p b 0.01, ***p b 0.001 compared with Mock-transfected group. (B) Effects of RalA on the endocytosis of D2R in SH-SY5Y cells. Cells expressing D2R (0.85 pmol/mg
protein) were transfected with WT-, G23V-, or S28N-RalA. Endocytosis assay was conducted as described in Materials and Methods. **p b 0.01, ***p b 0.001 compared with the Mock or
S28N-RalA group. P b 0.001 when G23V-RalA group was compared withWT-RalA group. (C) Effects of RalA on the endocytosis of β2AR. (Left panel) GFP-tagged β2AR was co-transfected
with eitherMock vector orHA-tagged RalA constructs. Cells were treatedwith 1 μM isoproterenol (ISO) for 20min and labeledwith antibodies to HA. The horizontal bar represents 10 μm.
Arrows represent β2AR located on the plasma membrane. Data represent results from two independent experiments with similar outcomes. (Right panel) Effects of RalA on the endocy-
tosis of β2ARmeasured by the radioligandmethod. Cells expressing β2AR (1.8 pmol/mg protein) were transfectedwith RalA constructs. Cells were treatedwith either the vehicle or 1 μM
ISO for 20 min. *p b 0.05, ***p b 0.001 compared with the WT- or S28N-RalA group. Each data point represents mean ± SEM (n = 6).
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ing GRK2 from the receptors
RalBP1 (RalA-binding protein 1) is a downstream target of RalA [27]
that interacts with POB1, a partner of RalBP1 [28], and is known to be
involved in the endocytosis of EGF and insulin receptor [11]. Unlike
EGF receptor (Figure S1), the deletion mutants of RalBP1 and POB1
did not affect the endocytosis of D2R (Figure S2A). PLD is another
well-known effector protein of Ral [10]. PLD inhibitors block agonist-
stimulated endocytosis of EGF, δ-opioid, and angiotensin type 1A
receptor [29–33]. However, treatment of cells with the PLD inhibitor
VU 0155069 did not have any effect on the endocytosis of D2R
(Figures S2B). In agreement with these results, ΔN11-G23V-RalA (a
RalA mutant with 11 amino acids deleted from its N-terminus, which
does not couple to PLD) inhibited the endocytosis of D2R to a similar
extent as G23V-RalA (Figure S2C). These results collectively suggested
that RalBP1, POB1, and PLD do not mediate the RalA-mediated inhibi-
tion of D2R endocytosis.
GRK2 and β-arrestins are established cellular components that drive
the endocytosis of GPCRs. To test whether GRK2 and β-arrestins are
involved in RalA-mediated inhibition of D2R endocytosis, biochemical
interactions between them were examined. As shown in Fig. 2A, inter-
action of GRK2 with active form RalA but not with WT-RalA or inactive
formRalA increased in response to agonist stimulation of D2R. The same
results were obtained from the studies of β2AR (Fig. 2B). These results
were also conﬁrmed with endogenous GRK2 (Figure S3). To locate the
subregions of GRK2 that interact with G23V-RalA, GST fusion proteins
were prepared for RGS homology (RH), catalytic (Cat), and Pleckstrin
homology (PH) domain of GRK2. As shown in Fig. 2C, the catalytic do-
main of GRK2 interacted with G23V-RalA. Since the GTP-bound status
of G23V-RalA is ﬁxed, it is likely that the increased enzymatic activity
of GRK2 which is mediated by activated D2R is the determining factor
that enhances the association between the two proteins. Indeed, active
RalAwas phosphorylated on the serine residue(s) when it was associat-
ed with GRK2 (Fig. 2D). In addition, the interaction between K220R-
GRK2, an enzymatic inactive mutant [34], and G23V-RalA did not
change in response to D2R activation (Fig. 2E). Since G23V-RalA
sequestered GRK2 from receptor, it was expected that D2R phosphory-
lation will be inhibited by G23V-RalA. As shown in Fig. 2F, agonist-
induced phosphorylation of D2R was inhibited when G23V-RalA was
co-expressed. These results indicate that GRK2 binds to RalA in a GTP-
selective manner, leading to decreases in association of GRK2 and D2R,
which results in the inhibition of phosphorylation and endocytosis of
D2R.
Since interaction between GRK2 and active RalA increased in
response to activation of D2R or β2AR, and because the phosphorylation
of D2R was blocked by active RalA, interaction between D2R and GRK2
was expected to be decreased by G23V-RalA. As shown in Fig. 3A,
interaction between D2R and GRK2 increased in response to agonist
stimulation and this increase was abolished when G23V-RalA was co-
expressed. Next we determined the effects of RalA on the interaction
between D2R and β-arrestin2. Since GRK2 mediates agonist-induced
receptor phosphorylation which facilitates the recruitment of β-
arrestins to the plasma membrane where receptors are located, inhibi-
tion of the interaction between receptor andGRK2will indirectly inhibit
the interaction between receptor and β-arrestin. Interaction between
D2R and β-arrestin2 was determined by β-arrestin translocation assay
[14]. As shown in the top panel of Figure S4, β-arrestin2 translocated to-
ward plasma membrane in response to agonist treatment. The translo-
cationwas signiﬁcantly inhibited in the cells expressingG23V-RalA (3rd
panel) but a less extent in the cells expressing WT-RalA (2nd panel).
To determinewhether RalA affects the interaction between receptor
and β-arrestin2 independently of receptor phosphorylation, we utilized
D2R-IC23. In D2R-IC23, all of the 15 serine and 12 threonine residues
located within the 2nd and 3rd intracellular loops were mutated to
alanine and valine residues, respectively. D2R-IC23 has been used tostudy receptor phosphorylation-independent processes [35]. Thus,
effects of RalA on the interaction between D2R-IC23 and β-arrestin2
exclude the effects of RalA on the GRK2-mediated facilitation of β-
arrestin recruitment. As shown in Fig. 3B, G23V-RalA did not have any
effect on the interaction between D2R-IC23 and β-arrestin2. Thus, it
could be postulated that active RalA selectively interfereswith the inter-
action between D2R and GRK2.
In accordance with these results, inhibitory activities of RalA on D2R
endocytosis occurred similarly in control and β-arrestin1/2-KD cells but
were signiﬁcantly reduced in GRK2-knockdown (GRK2-KD) cells (Fig.
3C & D). On the other hand, knockdown of GRK5, another GRK which
increases the endocytosis of D2R in an agonist-dependent manner
[14], did not affect the inhibitory activities of G23V-RalA on the endocy-
tosis of D2R (Fig. 3E).
3.3. Gβγ-mediated conversion of GTP-RalA to GDP-RalA is required for the
endocytosis of GPCRs
Our results fromHEK-293 and SH-SY5Y cells suggested that receptor
endocytosis would be constitutively being inhibited by active RalA both
for D2R and β2AR. Thus, it could be postulated that agonist-induced
conversion of GTP-RalA to GDP-RalA is needed for receptor endocytosis
to occur. To test this hypothesis, we selected two GPCRs that readily in-
ternalize (D2R, β2AR) and two GPCRs that rarely internalize (D3R, β1AR)
[14,36,37]. As shown in Fig. 4A and B, agonist stimulation of D2R or β2AR
resulted in inhibition of RalA (about 95 and 70%, respectively). In
contrast, stimulation of D3R orβ1AR did not inﬂuence the RalA activities.
Essentially the same results were obtained for the endogenous RalA in
SH-SY5Y cells in which D2R or D3R were stably expressed (Fig. 4C).
Thus, it could be hypothesized that activation of the GPCRs which
have tendency to undergo endocytosis mediate a decrement of RalA
activity. This hypothesis was corroborated by the studies of a chimeric
receptor between D3R and D2R, D3R-(IC2/3-D2R), in which the 2nd
and 3rd intracellular loops of D3R were replaced with those of D2R. In
D3R-(IC2/3-D2R), signaling properties remained the same but the
endocytic properties became opposite (Fig. 4D, lower panel) [14]. In
agreement with the results from Fig. 4A–C, agonist stimulation of D3R-
(IC2/3-D2R), but not D3R, resulted in an inhibition of RalA (Fig. 4D,
upper panel).
Next, we determined whether signaling through G protein is
required for the inhibition of RalA. For this, three GPCRs, which com-
monly undergo endocytosis but have different signaling pathways,
were selected (Fig. 4E). Pertussis toxin (PTX) treatment completely
and partly blocked the RalA inhibition mediated by D2R and β2AR,
respectively (Fig. 4E; compare 2/3 vs. 4/5 lanes in the upper panel of
the GST-pull down part). Since D2R and β2AR are coupled to Gi/o and
Gs/i [38], respectively, and AT1R to Gq, it is unlikely that a speciﬁc Gα
subtype was involved in the conversion of GTP-RalA to GDP-RalA. On
the other hand, GRK2-CT, which sequesters the Gβγ subunit, blocked
the RalA inhibition mediated by all of the three receptors, suggesting a
common involvement of Gβγ in the inhibition of RalA. AT1R belongs
to endocytic class B GPCRs which form stable intracellular receptor/β-
arrestin complexes after receptor endocytosis [39,40]. Agonist stimula-
tion of vasopressin type 2 receptor (V2R), another endocytic class B
GPCR also showed the same pattern of RalA inhibition (Figure S5).
These results suggest that Gβγ-mediated RalA inhibition could be a
common cellular mechanism to regulate receptor endocytosis regard-
less of signaling pathways and endocytic properties.
3.4. Characterization of D2R-mediated inhibition of RalA
Since inhibition of RalA is suggested to be related to the endocytosis
of GPCRs, wewanted to determinewhether receptor endocytosis medi-
ates the inhibition of RalA or whether inhibition of RalA is required for
the receptor endocytosis to occur. As shown in Fig. 5A, blockade of the
endocytosis of D2R by pretreatment with sucrose did not affect the
Fig. 2. Functional interaction between RalA and GRK2. (A) GTP-dependent interaction between RalA and GRK2. Cells expressing D2R (1.7 pmol/mg protein) were transfected with FLAG-
GRK2, alongwith RalA constructs, andwere treatedwith 10 μMDA for 1min. Cell lysateswere immunoprecipitatedwith FLAG beads and blottedwith antibodies to RalA and FLAG. Fold of
increase of immunoprecipitation was as follows: 1.67 ± 0.38 (WT), 3.93 ± 1.12 (G23V), 1.03 ± 0.32 (S28N). G23V group was signiﬁcantly different fromWT and S28N group (p b 0.05,
n=3). (B) Interaction betweenGRK2and active RalA in response toβ2AR stimulation. Cells expressingβ2AR (1.2pmol/mgprotein)were transfectedwith FLAG-GRK2andG23V-RalA, and
stimulated with 1 μM ISO for 1 min. Cell lysates were immunoprecipitated with FLAG beads and blotted with antibodies to RalA and FLAG. Fold of increase was 3.77 ± 1.22.
(C) Identiﬁcation of the GRK2 subdomains that interact with active RalA. GST fusion proteins were prepared for RH, and the catalytic and PH domains of GRK2. Cell lysates expressing
G23V-RalAwere incubatedwith GST fusion proteins. Eluents were immunoblottedwith antibodies to RalA. Squares in the lower panel represent GST fusion proteins of GRK2 subdomains.
Data represent results from two independent experiments with similar outcomes. (D) GRK2-mediated phosphorylation of active RalA in response to agonist stimulation of D2R. HEK-293
cells expressing D2R (1.7 pmol/mg protein) were transfected with FLAG-tagged G23V-RalA and GRK2 in pCMV5. Cells were stimulated with 10 μM DA for 1 min. Cell lysates were
immunoprecipitated with FLAG beads and immunoprecipitates were blotted with antibodies to FLAG, GRK2, and phosphoserine. Data represent results from four independent experi-
ments with similar outcomes. (E) Effects of enzymatic activities of GRK2 on the interaction with active RalA. HEK-293 cells stably expressing D2R (1.7 pmol/mg protein) were transfected
with G23V-RalA alongwith FLAG-taggedWT-GRK2 or K220R-GRK2. Cells were treatedwith 10 μMDA for 1min. Cell lysateswere immunoprecipitatedwith FLAG beads, and blottedwith
antibodies to RalA and FLAG. Fold of increase forWT-GRK2 and K220R-GRK2was 3.33 ± 0.90 and 1.03± 0.32, respectively (p b 0.05, n= 3). (F) Effects of RalA on agonist-induced phos-
phorylation of D2R. HEK-293 cellswere transfectedwith FLAG-D2R (2.1 pmol/mgprotein) alongwith RalA constructs. Receptor phosphorylationwas determined after 5min of stimulation
with 10 μM DA. Cell lysates were immunoprecipitated with FLAG beads. The phosphorylated receptors were visualized by autoradiography and the total receptors were detected with
antibodies to rabbit FLAG antibodies (lower panel). Data represent results from two independent experiments with similar outcomes.
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clathrin-mediated receptor endocytosis was blocked by co-expression
of epsin (204–458), a dominant negative mutant of epsin [11] (Fig.
5B). On the other hand, when D2R is mutated so that it cannot undergo
endocytosis through exchange of the 2nd and 3rd intracellular loops
with those of D3R, D2R-(IC2/3-D3R), the ability to inhibit RalAwas abro-
gated (Fig. 5C). These results suggested that RalA would still be
inhibited as far as the receptor have the propensity to internalize,
even if receptor endocytosis was blocked by external treatments actingdownstream of the endocytic cascade. These results suggested that
agonist-induced RalA inhibition would be an upstream event for recep-
tor endocytosis, rather than a post-endocytic event.
GRK2-mediated receptor phosphorylation is a well-established
cellular event that initiates receptor endocytosis. A mutant of D2R,
D2R-IC23 which was used in Fig. 3B was employed to determine the
relationship between RalA inhibition and receptor phosphorylation.
D2R-IC23 is phosphorylation deﬁcient, but still undergoes endocytosis
[35]. As shown in Fig. 5D, RalA was inhibited when either D2R or D2R-
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processes located upstream of receptor phosphorylation.
3.5. EGF inhibits GPCR endocytosis by activating RalA
HEK-293 cells endogenously express various plasma membrane
receptors and related signaling components [22]. We wanted to deter-
minewhether the principles obtained from the over-expressed proteins
could be applied to endogenous receptors such as EGFR and LPA1R.
When cells were treated with LPA, LPA1R underwent endocytosis (Fig.
6A) and RalA was inhibited at 1 min and returned near basal level at
15 min (Fig. 6B).
When cells were treatedwith EGF, RalA activitieswere elevated (Fig.
6C). As expected from the inhibitory activities of active RalA on receptor
endocytosis, endocytosis of D2R was inhibited when cells were treated
with EGF (Fig. 6D, compare Mock groups of Veh-treated and EGF-
treated cells). Also the inhibitory activities WT-RalA became similar to
those of G23V-RalAwhen cells were treatedwith EGF probably because
WT-RalA was switched to active RalA. In addition, inhibitory activities
effects of EGF on the endocytosis of D2R were abolished in RalA-KD
cells (Fig. 6E), suggesting that inhibitory activities of EGF treatment on
the D2R endocytosis occurred through activation of RalA.
As expected from the stimulatory effects of EGF on RalA activites
and from the inhibitory effects of active RalA on GPCR endocytosis,
pre-treatment with EGF inhibited LPA-induced endocytosis of
LPA1R (Fig. 7A). Also EGF treatment increased the interaction of
endogenous GRK2 with endogenous RalA (Fig. 7B) but inhibited
the interaction of GRK2 with LPA1R (Fig. 7C).
3.6. Interaction between RalA and RGL, a guanine nucleotide exchange
factor, is inhibited in response to the activation of GPCRs which have
tendency to undergo endocytosis
Ral GDP dissociation stimulator-like (RGL) is one of the guanine
nucleotide exchange factors (GEFs) of Ral [41,42]. Presently, RGL
stimulated the GDP → GTP exchange and increased the GTP-bound
state of RalA (Figure S6A) and RGL was tested for D2R endocytosis.
As shown in Figure S6B, RGL inhibited the endocytosis of D2R and
its inhibitory activities were signiﬁcantly reduced when endogenous
RalA was knocked down. In agreement with the results from RalA, in-
hibitory activities of RGL on D2R endocytosis were abolished in
GRK2-KD cells but were intact in β-arrestins-KD cells (Figures S6C
and S6D).
Since RalA was inhibited in response to agonist stimulation of the
GPCRs which have tendency to undergo endocytosis in a Gβγ-
dependent manner, we hypothesized that the inhibition of RalA was
achieved by Gβγ-mediated dissociation of RGL from RalA. As shown in
Fig. 8A, RGL dissociated from RalA in response to D2R stimulation
(compare the 2nd & 3rd lane) in a Gβγ-dependent manner (compare
lanes 4 and 5). Virtually the same results were obtained with theFig. 3.GRK2 is involved in theRalA-mediated inhibition of D2R endocytosis. (A) Effects of RalA on
D2R, alongwith RalA constructs. Cells were treatedwith 10 μMDA for 1min. Cell lysateswere in
(80 kDa) andRalA. Fold of increase of immunoprecipitationwas as follows: 4.27±1.10 (WT), 1.
S28N group (p b 0.05, n= 3). (B) Effects of RalA on the interaction between non-phosphorylata
alongwith RalA constructs. Cellswere treatedwith 10 μMDA for 1min. Cell lysateswere incuba
(45 kDa) and RalA. Fold of increase of immunoprecipitationwas as follows: 3.67±1.55 (WT), 3.
inhibition of D2R endocytosis. HEK-293 cells stably expressing control shRNA or β-arrestin1/2
were maintained around 1.4 pmol/mg protein. About 85% and 70% of cellular β-arrestin1 and
with each Mock group (n = 6). ### p b 0.001 compared with Con-KD/Mock group. P b 0.00
G23V-RalA group was compared with WT-RalA group. (D) Roles of GRK2 in the RalA-mediate
shRNA constructs were transfected with D2R along with RalA constructs. Receptor expression
down. ***p b 0.001 compared with the Mock group, ### p b 0.001 compared with Con-KD/Mo
in Con-KD cells. P b 0.001 when G23V-RalA group was compared with S28N-RalA group in C
293 cells stably expressing control shRNA or GRK5 shRNA constructs were transfected with
1.7 pmol/mg protein. About 70% of GRK5 was knocked down. * p b 0.05, ** p b 0.01, ***p b 0
(n = 6). P b 0.05 when WT-RalA group was compared with S28N-RalA group in Con-KD cells
Con-KD cells and GRK5-KD cells, respectively.stimulation of β2AR, but not D3R (Figure S7A). On the other hand,
D2R-mediated interaction between Gβγ and RGL increased (Fig. 8B)
and the time course of their association coincided with that of RalA in-
hibition (Fig. 8C). These results were conﬁrmed by immunocytochemi-
cal studies. At the basal state, Gβγ, RGL, and RalA co-localized on the
plasma membrane of the cells which stably express D2R (Fig. 8D, left
panel).When the cellswere treatedwithDA (Fig. 8D, right panel), inter-
action between Gβγ and RGL became evident, and they translocated to
the cytosolic region and colocalized. As a result, they were separated
from the RalA which was still associated with the plasma membrane
(indicated by arrows). Translocation of RGL was less clear in the cells
expressing D3R, which does not undergo endocytosis, and large propor-
tion of RalA and RGL remained co-localized on the plasma membrane
both before and after agonist stimulation (Figure S7B).4. Discussion
The present study reveals a novel regulatory mechanism involved in
the endocytosis of GPCRs. As shown in the diagram of Fig. 9, conversion
of GTP-RalA to GDP-RalA is a critical cellular event that allows receptor-
mediated endocytosis to occur. The most notable ﬁnding in this work is
that it provides a principle that could predict the occurrence of GPCR
endocytosis regardless of their signaling pathways (Gs, Gi/o, Gq) or
endocytic properties (class A or class B). Active (GTP-bound) RalA has
high afﬁnity to GRK2 and inhibits the endocytosis of GPCRs by seques-
tering active GRK2 from its effectors including the agonist-primed
receptors. RalA is selectively inhibited by agonist stimulation of the
GPCRs which have tendency to undergo endocytosis and inhibition of
RalA occurs as long as the GPCR possesses the propensity to undergo
endocytosis. Conversion of active RalA to inactive RalA which has low
afﬁnity to GRK2 allows interaction between receptor and GRK2. These
results suggest that the endocytosis of certain GPCRs is regulated by
the ability of each receptor to inhibit RalA activities.
The diagram in Fig. 9 was proposed based on following results. Gβγ
and GRK2 is constitutively associated near (or on) the plasma mem-
brane (Fig. S8A, Veh-treated), and they dissociate in response to agonist
stimulation (Fig. S8A. ISO-treated & Fig. S8B). When cells are treated
with agonist, Gβγ transiently interacts with receptor (Fig. S8C) and
translocates to cytosol (Fig. 8D). RGL dissociates from active RalA in a
Gβγ-dependent manner (Fig. 8A), interacts with Gβγ (Fig. 8B), and
translocates toward the cytosol in association with Gβγ (Fig. 8D). The
GRK2 which is dissociated from Gβγ interacts with GTP-RalA though
catalytic domain (Fig. 2A, B, C). As RGL dissociates from active RalA
and translocates to the cytosol as a complex with Gβγ (Fig. 8A, B, D),
GTP-RalA is converted to GDP-RalA which has low afﬁnity for GRK2.
GRK2 is now free and is recruited to the plasma membrane (Fig. S8A)
and interacts with receptor (Fig. 3A).
According to the well-established paradigm of GRK functions on
GPCR internalization, GRKs phosphorylate theGPCR, and then the phos-
phorylated receptor recruits β-arrestins that target the receptor to thethe interaction betweenD2R andGRK2. HEK-293 cellswere transfectedwith GRK2, FLAG-
cubatedwith 25 μl FLAG beads, and eluents were immunoblottedwith antibodies to GRK2
07±0.64 (G23V), 4.17±1.23 (S28N).WT groupwas signiﬁcantly different fromG23Vand
ble D2R and β-arrestin2. HEK-293 cells were transfectedwith β-arrestin2, FLAG-D2R-IC23,
tedwith 25 μl FLAG beads, and eluentswere immunoblottedwith antibodies toβ-arrestin2
77±1.40 (G23V), 3.27±1.46 (S28N, n=3). (C) Roles ofβ-arrestins in the RalA-mediated
shRNA were transfected with D2R along with RalA constructs. Receptor expression levels
β-arrestin2 was knocked down, respectively. *p b 0.05, **p b 0.01, ***p b 0.001 compared
1 when WT- or G23V-RalA group was compared with S28N-RalA group. P b 0.05 when
d inhibition of D2R endocytosis. HEK-293 cells stably expressing control shRNA or GRK2
levels were maintained around 1.8 pmol/mg protein. About 90% of GRK2 was knocked
ck group (n = 6). P b 0.001 whenWT-RalA group was compared with S28N-RalA group
on-KD cells. (E) Roles of GRK5 in the RalA-mediated inhibition of D2R endocytosis. HEK-
D2R along with RalA constructs. Receptor expression levels were maintained around
.001 compared with the Mock group, ## p b 0.01 compared with Con-KD/Mock group
. P b 0.001 and p b 0.01when G23V-RalA group was compared with S28N-RalA group in
Fig. 4. Selective regulation of RalA activities through theGPCRswhich have tendency to undergo endocytosis. (A) Effects of stimulation of D2R andD3R on the RalA activities. HEK-293 cells
were transfectedwith RalA togetherwith D2R or D3R in pCMV5, andwere stimulatedwith 10 μMDA for 1min. Bacterial lysates containing theGST fusion proteins of RBDweremixedwith
the cell lysates. The eluents were analyzed with SDS-PAGE gel and the blots were probed with antibodies to RalA (28 kDa). About 95% of GTP-RalA was decreased by DA treatment. Re-
ceptor expression levels of D2R and D3R were 1.2 and 1.7 pmol/mg protein, respectively. Data represent results from two independent experiments with similar outcomes. (B) Effects of
stimulation ofβ1ARandβ2ARon the RalA activities. Cellswere transfectedwith RalA togetherwithβ1ARorβ2AR in pCMV5, and stimulatedwith 1 μM ISO for 1min. About 70% ofGTP-RalA
was decreased by ISO treatment in the cells expressing β2AR. Receptor expression levels of β1AR and β2AR were 1.4 and 0.95 pmol/mg protein, respectively. Data represent results from
two independent experiments with similar outcomes. (C) Regulation of endogenous RalA activities in response to agonist stimulation of D2R or D3R. SH-SY5Y cells which stably express
D2R (1.2 pmol/mg protein) or D3R (1.4 pmol/mg protein) were stimulated with 10 μM DA for 1 min. About 95% of GTP-RalA was decreased by DA treatment in the cells expressing D2R.
Data represent results from two independent experimentswith similar outcomes. (D) Effects of altering endocytic properties betweenD2R andD3R on the inhibition of RalA activities. Cells
were transfected with RalA alongwith D2R, D3R, or D3R-(IC2/3-D2R), and stimulated with 10 μMDA for 1 min. About 70–80% of GTP-RalA was decreased by DA treatment in the cells ex-
pressing D2R or D3R-(IC2/3-D2R). Data represent results from two independent experiments with similar outcomes. ***: p b 0.001 compared with D2R and D3R-(IC2/3-D2R) group.
(E) Roles of Gα and Gβγ subunits in the RalA inhibitions through the receptors which have tendency to undergo endocytosis. Cells were transfected with RalA together with 1.5 μg
D2R, β2AR, or angiotensin type 1 receptor (AT1R) in pCMV5, and treated with 10 μM DA, 1 μM ISO, or 1 μM angiotensin II for 1 min. Cells were either treated with PTX (100 ng/ml) or
transfected with 4 μg of the carboxy-terminal domain of GRK2 (GRK2-CT) in pRK5 in a 100 mm culture dish. About 60–90% of GTP-RalA was decreased by treatment with an agonist
for each receptor in Mock/Vehicle condition. Similar RalA inhibitions were observed by stimulation of AT1R in the presence and absence of PTX treatment. Data represent results from
four independent experiments with similar outcomes.
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quite hard to understand how G23V-RalA (or even WT-RalA) blocks
D2R endocytosis in the absence of β-arrestins. Previously we have
reported that D2R undergoes both clathrin-mediated endocytosis(CME) and caveolar endocytosis, and that only phosphorylated recep-
tors undergo CME [43]. We also showed that D2R-IC23, a non-
phosphorylatable D2R, undergoes non-CME process (caveolar or
unidentiﬁed endocytosis) [43]. As shown in Fig.S9A, GRK2 still increases
Fig. 5.Roles of receptor endocytosis and phosphorylation on the regulation of RalA activities. (A) Relationship between receptor endocytosis and regulation of RalA.HEK-293 cells express-
ing D2R were treated with 0.45 M sucrose for 20 min, followed by 10 μMDA for 1 h. Receptor expression levels were maintained around 0.85 pmol/mg protein. ***: p b 0.001 compared
with thevehicle group (n=3). For thedetermination of changes inRalA activities, cells expressingD2Rwere transfectedwith RalA, and treatedwith 10 μMDA for 1min after pretreatment
with vehicle or sucrose. DA-induced decrease in GTP-RalA was 63.5 ± 12.5 and 72.4 ± 15.7% (n= 3) in vehicle- and DA-treated group, respectively. (B) Relationship between clathrin-
mediated receptor endocytosis and regulation of RalA HEK-293 cells were transfected D2R with or without Epsin (204–458). Receptor expression levels were maintained around
1.8 pmol/mg protein. ***p b 0.01 compared with the Mock group (n = 3). For the determination of changes in RalA activities, cells were treated with 10 μM DA for 1 min, and levels of
active RalA were determined. GTP-RalA was decreased about 90–95% by DA treatment in the cells transfected with either Mock vector or epsin (204–458). Data represent results from
two independent experiments with similar outcomes. (C) Relationship between endocytic properties of D2R and RalA activities. HEK-293 cells were transfected with D2R or D2R-(IC2/
3-D3R) and receptor expression levelswere adjusted about 1.4–1.7 pmol/mgprotein. ***p b 0.01 comparedwithD2R group (n=3). About 90% of GTP-RalAwasdecreased byDA treatment
in the cells expressing D2R. Data represent results from two independent experiments with similar outcomes. (D) Roles of receptor phosphorylation on the inhibition of RalA. HEK-293
cells were transfected with RalA along with D2R or D2R-IC23, and treated with 10 μM DA for 1 min. Receptor expression levels were maintained around 1.7 pmol/mg protein. About
80–85% of GTP-RalA was decreased by DA treatment in the cells expressing D2R or D2R-IC23. Data represent results from two independent experiments with similar outcomes.
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Fig. 6. Functional interactions among RalA, LPAR1, and EGFR. (A) Role of RalA activity in the LPAR1 endocytosis. HEK-293 cells were co-transfectedwithHA-tagged human LPAR1 andGFP-
taggedWT-, G23V- or S28N-RalA. Cellswere stimulatedwith 10 μMlysophosphatidic acid (LPA) for 20min. The scale bar represents 10 μm.Representative imageswere selected fromeach
experimental group. (B) Effect of LPAR1 stimulation on RalA activity. HEK-293 cells expressing HA-tagged human LPAR1 were stimulated with 10 μM LPA for 1–15 min. Between 70 and
80% of GTP-RalA was decreased when cells were treated with LPA for 1 min. Data represent results from two independent experiments with similar outcomes. (C) Effects of EGFR stim-
ulation on RalA activity. HEK-293 cells were treated with 100 ng/ml EGF for 20 min with or without pretreatment with 1 μM AG1478 for 30 min. Data represent results from two inde-
pendent experimentswith similar outcomes. (D) Effects of EGF treatment on theRalA-mediated regulation of D2R internalization. Cells expressingD2R (1.4 pmol/mgprotein) and different
RalA constructs were treatedwith vehicle or 100 ng/ml EGF for 20min, followed by treatment with 10 μMDA for 1 h. **p b 0.01, ***p b 0.001 comparedwith eachMock group. ##p b 0.01
when comparedwithMock/vehicle-treated group. (E)RalA is required for the inhibitory effects of EGF treatment on the internalization of D2R. Cells expressing D2R (1.7 pmol/mg protein)
were pretreated eitherwith vehicle or 100 nMEGF for 20min, followedby treatmentwith 10 μMDA for 1 h. About 70% of cellular RalAwas decreased inRalA-KD cells. **p b 0.01 compared
with Con-KD/vehicle-treated group.
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processes are available. However, effects of GRK2 on the internalization
of D2R-IC23 are abolished in Cav1-KD cells in which both CME and
caveolar endocytosis are absent, suggesting that GRK2 could mediate
both CME and caveolar endocytosis. In addition, interaction betweenGRK2 and caveolin1 is increased in response to agonist stimulation of
β2AR (Fig.S9B).
It is noticeable that RalA does not affect the endocytosis which is
mediated by β-arrestins, another critical cellular component responsi-
ble for GPCR endocytosis. A recent study has shown that both β2AR
Fig. 7. EGFR-mediated activation of RalA sequesters GRK2 from LPAR1. (A)Effects of EGFR activation on the endocytosis of LPAR1. Cells expressing HA-tagged LPAR1 were treated with
either vehicle or 100 ng/ml EGF for 20 min, followed by 10 μM LPA for 20 min. Cells were labeled with anti-HA antibodies at a dilution of 1:500 for 1 h at room temperature, followed
by labeling with rabbit Alexa-594 at a 1:500 dilution. Horizontal bar represent 10 μM. (B)Effects of EGFR activation on the interaction between endogenous RalA and GRK2. HEK-293
cells were treated with either vehicle or 100 ng/ml EGF for 20 min. Cell lysates were immunoprecipitated with antibodies against RalA, and immunoprecipitates were blotted with anti-
bodies to GRK2. Data represent results from two independent experimentswith similar outcomes. (C) Effects of EGFR activation on the interaction between endogenous LPAR1 and GRK2.
Cells were treatedwith either vehicle or 100 ng/ml EGF for 20min. Cell lysateswere immunoprecipitatedwith antibodies to LPAR1, and immunoprecipitates were blottedwith antibodies
to GRK2. Data represent results from two independent experiments with similar outcomes.
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including clathrin-mediated, caveolar as well as unidentiﬁed endocytic
pathway(s) [43]. In order to understand the relationship between
RalA-mediated regulation of GPCR endocytosis and the speciﬁc micro-
domains involved, functional roles of GRK2 and β-arrestins in each
endocytic pathway are needed to be clariﬁed.
It is generally accepted that binding of Gβγ and lipids such as PIP2 to
the PH domain of GRK2 mediates receptor phosphorylation and
membrane association of the kinase [44–48]. However, detailed
molecular mechanisms of the intermediate steps, such as intracellular
trafﬁcking properties of Gβγ before and after interaction with GRK2 or
involvement of intermediate cellular components which affect their
interactions, are still unclear. Our results might provide some clue
regarding the intermediate mechanisms that regulate the interactions
among receptor, Gβγ, and GRK2.
GPCRs are classiﬁed into class A and class B, depending on their
endocytic properties [39]. Endocytic class A GPCRs, such as β2AR and
D2R, establish a transient interaction with β-arrestin and dissociate
from β-arrestin when they enter the cytosol as endocytic vesicles.
Endocytic class B GPCRs, such as AT1A receptor and vasopressin type 2
receptor, establish a stable interaction with β-arrestin and co-localize
in endosomes after being internalized. Presently, both endocytic class
A and class B GPCRs inhibited RalA as far as they have tendency to un-
dergo endocytosis, suggesting that the principles established in this
study can be applied regardless of the post-endocytic fate of the
receptor.
Our results from D2R and β2AR show that GRK2, rather than RalBP1,
is involved in the regulation of receptor endocytosis. GRK2 preferential-
ly binds to active RalA rather than to the receptors, resulting indiminished receptor endocytosis. Similar to our results, a recent study
showed that RalA interacts with GRK2 and that their interaction is
prompted by activation of the LPA1 receptor [49]. Thus, it could be
speculated that single transmembrane receptors and the seven
transmembrane receptors employ RalBP1 and GRK2, respectively, to
induce receptor proteins to connect to endocytosis adaptors such as
AP-2.
In summary, present study reveals a novel regulatory mechanism
involved in the endocytosis of GPCRs. Conversion of GTP-RalA to GDP-
RalA is a critical cellular event that allows receptor-mediated endocyto-
sis to occur. The importance of this work is that it provides a principle
that could predict the occurrence of GPCR endocytosis.Conﬂict of interest
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Fig. 8.Molecularmechanisms involved in theD2R-mediated inhibition of RalA. (A) Involvement of theGβγ subunit in theD2R-mediated dissociation of RGL fromRalA. Cells expressingD2R
(1.7 pmol/mg protein)were transfectedwith GFP-RGL (105 kDa), FLAG-RalA, and/or GRK2-CT (20 kDa). Cellswere treatedwith 10 μMDA for 1min. Cell lysateswere immunoprecipitated
with FLAG beads and blotted with antibodies to GFP, GRK2, and FLAG. ***p b 0.001 compared with other RGL/RalA groups. ###p b 0.001 compared with RGL or RGL/RalA/DA group.
(B) Time course of the interaction between RGL and Gβ1 (36 kDa). Cells stably expressing D2R were transfected with GFP-RGL along with FLAG-Gβ1. Cells were treated with vehicle or
with 10 μM DA for 0-15 min. Cell lysates were immunoprecipitated with FLAG beads and blotted with antibodies to GFP. Interaction between RGL and Gβ1 increased 4.2 ± 1.2
(1 min) and 2.9 ± 1.1 (15 min) folds in response to agonist stimulation of D2R (p b 0.05, n = 3). (C) Time course of RalA inhibition. The cells which stably express D2R were transfected
with GFP-RalA. Cells were treatedwith 10 μMDA for 0–15min. Level of GTP-RalAwas 100±21.8 (0min), 38.7± 11.2 (1min), and 66.7± 12.6 (15min). Therewas statistical differences
between ‘1 min’ group and other groups (p b 0.05, n = 3). (D) Dissociation between RGL and RalA by agonist stimulation of D2R determined by immunocytochemistry. Cells stably ex-
pressing D2R were transfected with FLAG-Gβ1 along with GFP-RGL and HA-RalA. Cells were treated with vehicle (left panel) or with 10 μMDA for 5 min (right panel). Cells were labeled
with FLAG and HA antibodies at 1:1000 dilutions, followed by Alexa 555- and Alexa 647- conjugated secondary antibodies at 1:500 dilutions. The horizontal bar represents 10 μm. Arrows
represent RalA on the plasma membrane.
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Fig. 9.Diagram showingGβγ-mediated conversion of GTP-bound to GDP-bound RalA in response to agonist stimulation of internalizingGPCRs. GRK2 is bound to Gβγ through PHdomain.
In response to agonist stimulation, Gβγ dissociates from GRK2 and translocates toward cytosol as a complex with RGL, resulting in the dissociation of RGL from RalA. GRK2 which is dis-
sociated from Gβγ interacts with GTP-RalA which is associated with RGL through the catalytic domain of GRK2. As RGL translocates to cytosol as a complex with Gβγ, GTP-RalA is con-
verted to GDP-RalA to which GRK2 has low afﬁnity. GRK2 which is released in the cascade of RalA inhibition is ready for the interaction with receptor or other endocytic machineries.
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